NCT02806349

Brief Summary

The purpose of this study was to determine whether the co-administration of a konjac-glucomannan fibre blend and American ginseng in a randomized, placebo-controlled, cross-over trial can improve diabetes management.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at below P25 for phase_2 diabetes-mellitus-type-2

Timeline
Completed

Started Mar 2002

Longer than P75 for phase_2 diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2002

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2004

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2005

Completed
11 years until next milestone

First Submitted

Initial submission to the registry

March 2, 2016

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 20, 2016

Completed
Last Updated

June 20, 2016

Status Verified

June 1, 2016

Enrollment Period

2.7 years

First QC Date

March 2, 2016

Last Update Submit

June 15, 2016

Conditions

Keywords

American ginsengKonjac glucomannan fiber

Outcome Measures

Primary Outcomes (1)

  • HbA1c

    Difference at week 12 between control and test intervention

    Week 12

Secondary Outcomes (10)

  • Total Cholesterol

    Week 12

  • High sensitivity C reactive protein

    Week 12

  • Apolipoprotein A and B

    Week 12

  • Oxidized LDL

    Week 12

  • Blood pressure

    Week 12

  • +5 more secondary outcomes

Other Outcomes (6)

  • AST

    Week 12

  • creatinine

    Week 12

  • Clotting factors

    Week 12

  • +3 more other outcomes

Study Arms (2)

Control

PLACEBO COMPARATOR

3g/d Cornstarch and 14g/d wheat bran control

Dietary Supplement: Control

K-GB&AG

EXPERIMENTAL

3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend

Dietary Supplement: American GinsengDietary Supplement: Konjac-glucomannan fiber blend

Interventions

American GinsengDIETARY_SUPPLEMENT

herb

Also known as: Panax quinquefolius L.
K-GB&AG

Blend of 2 viscous fibers: konjac mannan and xanthan

K-GB&AG
ControlDIETARY_SUPPLEMENT

Fiber matched control for intervention (corn starch and wheat bran)

Control

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of type 2 diabetes of at least 1 year
  • age between 40 and 75 years old
  • treated with diet and anti hyperglycemic medications
  • HbA1c between 6.5% and 8.4%
  • Systolic blood pressure \<140mmHg
  • Diastolic blood pressure \<90mmHg
  • Clinically euthyroid
  • Normal renal and liver function

You may not qualify if:

  • treated with insulin
  • age less than 40 or older than 75 years old at the start of the trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Risk Factor and Modification Centre

Toronto, Ontario, M5C 2T2, Canada

Location

Related Publications (1)

  • Jenkins AL, Morgan LM, Bishop J, Jovanovski E, Jenkins DJA, Vuksan V. Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial. Eur J Nutr. 2018 Sep;57(6):2217-2225. doi: 10.1007/s00394-017-1496-x. Epub 2017 Jul 7.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Asian ginseng

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Vladimir Vuksan, PhD

    Unity Health Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Senior Scientist

Study Record Dates

First Submitted

March 2, 2016

First Posted

June 20, 2016

Study Start

March 1, 2002

Primary Completion

November 1, 2004

Study Completion

March 1, 2005

Last Updated

June 20, 2016

Record last verified: 2016-06

Data Sharing

IPD Sharing
Will not share

Locations